Roche cancer drug taking bite out of Bristol's Opdivo

ZURICH, Jan 27 (Reuters) - Roche's cancer drug

Tecentriq hit the market months behind immuno-oncology (I/O)

medicines from Merck and Bristol-Myers Squibb Co

but the Swiss drugmaker's treatment is making up lost ground.

Read more